BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29407882)

  • 1. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
    Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
    Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
    Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
    Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
    Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
    Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
    Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
    Crosland P; Maconachie R; Buckner S; McGuire H; Humphries SE; Qureshi N
    Atherosclerosis; 2018 Aug; 275():80-87. PubMed ID: 29879685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
    Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
    J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands.
    Marang-van de Mheen PJ; ten Asbroek AH; Bonneux L; Bonsel GJ; Klazinga NS
    Eur Heart J; 2002 Dec; 23(24):1922-30. PubMed ID: 12473254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.
    Kerr M; Pears R; Miedzybrodzka Z; Haralambos K; Cather M; Watson M; Humphries SE
    Eur Heart J; 2017 Jun; 38(23):1832-1839. PubMed ID: 28387827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia.
    Lázaro P; Pérez de Isla L; Watts GF; Alonso R; Norman R; Muñiz O; Fuentes F; Mata N; López-Miranda J; González-Juanatey JR; Díaz-Díaz JL; Blasco AJ; Mata P
    J Clin Lipidol; 2017; 11(1):260-271. PubMed ID: 28391894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.
    Hendy LE; Spees LP; Tak C; Carpenter DM; Thomas KC; Roberts MC
    Atherosclerosis; 2024 Jun; 393():117541. PubMed ID: 38677159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
    Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
    Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review.
    Rosso A; Pitini E; D'Andrea E; Massimi A; De Vito C; Marzuillo C; Villari P
    Ann Ig; 2017; 29(5):464-480. PubMed ID: 28715059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
    Chen CX; Hay JW
    Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.
    Marquina C; Lacaze P; Tiller J; Riaz M; Sturm AC; Nelson MR; Ference BA; Pang J; Watts GF; Nicholls SJ; Zoungas S; Liew D; McNeil J; Ademi Z
    Eur Heart J; 2022 Sep; 43(34):3243-3254. PubMed ID: 34788414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands.
    Ademi Z; Norman R; Pang J; Sijbrands E; Watts GF; Hutten BA; Wiegman A
    JAMA Pediatr; 2023 Jun; 177(6):625-632. PubMed ID: 37126315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
    Ferguson TW; Tangri N; Tan Z; James MT; Lavallee BDA; Chartrand CD; McLeod LL; Dart AB; Rigatto C; Komenda PVJ
    Kidney Int; 2017 Jul; 92(1):192-200. PubMed ID: 28433383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.